Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-09

AUTHORS

P. Müller, G. Flesch, M. de Gasparo, M. Gasparini, H. Howald

ABSTRACT

OBJECTIVE: Pharmacokinetics, pharmacodynamic effects and tolerability of 200 mg valsartan, once-daily for 8 days, were investigated in 16 healthy, normotensive volunteers on a normal sodium diet. METHODS: This was a double-blind, placebo-controlled, randomized crossover study. Drug concentrations in plasma and urine, angiotensin II (Ang II) concentrations in plasma, systolic (SBP) and diastolic (DBP) blood pressure, heart rate (HR) in the supine position and 3 min after passive head-up tilting, as well as safety parameters (ECG, clinical chemistry and hematology, renal water and electrolyte excretion) were measured over 24 h after the first dose (day 1) and at steady state on day 8. RESULTS: Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8). Less than 10% of the dose was excreted unchanged in urine. The increase in plasma Ang II (Cmax, 6 h) was significantly enhanced at steady state. Supine SBP and DBP significantly decreased on day 8 only, by an average of -3.6 and -2.4 mmHg, respectively, versus placebo, without a concomitant increase in HR. Upon passive tilting, the increase in DBP, normally reinforced by sympathetic renin release, was slightly but significantly blunted on day 1 (-2.0 mmHg) and day 8 (-4.0 mmHg) of treatment with valsartan versus placebo. The orthostatic reflex increase in HR was slightly enhanced compared with placebo by an average of 2.8 beats min-1 on day 1 and by 2.9 beats.min-1 on day 8. Valsartan was well tolerated and had no influence on ECG, clinical laboratory parameters, and water, electrolyte and uric acid excretion. CONCLUSIONS: Pharmacokinetics of valsartan are unchanged after multiple once-daily dosing, with little (expected) accumulation in plasma. Effects of 200 mg valsartan on blood pressure in healthy subjects on a normal sodium intake are small and become more prominent after repeated dosing. Indirect evidence of AT1 blockade by valsartan is demonstrated by an increase of plasma Ang II and by a blunted DBP response to passive tilting. The decrease in blood pressure at steady state enhances the increase in plasma Ang II. Valsartan is well tolerated and is devoid of effects on water, electrolyte and uric acid excretion at 200 mg per day in healthy normotensive volunteers. More... »

PAGES

441-449

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050317

DOI

http://dx.doi.org/10.1007/s002280050317

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053532490

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9342579


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metabolic Clearance Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valsartan", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller", 
        "givenName": "P.", 
        "id": "sg:person.0601746477.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601746477.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flesch", 
        "givenName": "G.", 
        "id": "sg:person.0614511442.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614511442.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Gasparo", 
        "givenName": "M.", 
        "id": "sg:person.0607272272.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607272272.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gasparini", 
        "givenName": "M.", 
        "id": "sg:person.01344643055.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344643055.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howald", 
        "givenName": "H.", 
        "id": "sg:person.01363715465.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363715465.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1016/s0009-9236(97)90180-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008026001", 
          "https://doi.org/10.1016/s0009-9236(97)90180-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199609000-00016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013550162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1992.56", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022704315", 
          "https://doi.org/10.1038/clpt.1992.56"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.22.3.339", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024651994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00266358", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025911538", 
          "https://doi.org/10.1007/bf00266358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00266358", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025911538", 
          "https://doi.org/10.1007/bf00266358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600810324", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025971911"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/0009-9236(95)90020-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032911978", 
          "https://doi.org/10.1016/0009-9236(95)90020-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.53.3.400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034907386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0009-9236(96)90061-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042542216", 
          "https://doi.org/10.1016/s0009-9236(96)90061-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(89)92133-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049274476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1993.tb05696.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052278669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/cs0900205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056728675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/cs0900205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056728675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ageing/15.1.17", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059367722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajh/7.12.1035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082472164"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-09", 
    "datePublishedReg": "1997-09-01", 
    "description": "OBJECTIVE: Pharmacokinetics, pharmacodynamic effects and tolerability of 200 mg valsartan, once-daily for 8 days, were investigated in 16 healthy, normotensive volunteers on a normal sodium diet.\nMETHODS: This was a double-blind, placebo-controlled, randomized crossover study. Drug concentrations in plasma and urine, angiotensin II (Ang II) concentrations in plasma, systolic (SBP) and diastolic (DBP) blood pressure, heart rate (HR) in the supine position and 3 min after passive head-up tilting, as well as safety parameters (ECG, clinical chemistry and hematology, renal water and electrolyte excretion) were measured over 24 h after the first dose (day 1) and at steady state on day 8.\nRESULTS: Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8). Less than 10% of the dose was excreted unchanged in urine. The increase in plasma Ang II (Cmax, 6 h) was significantly enhanced at steady state. Supine SBP and DBP significantly decreased on day 8 only, by an average of -3.6 and -2.4 mmHg, respectively, versus placebo, without a concomitant increase in HR. Upon passive tilting, the increase in DBP, normally reinforced by sympathetic renin release, was slightly but significantly blunted on day 1 (-2.0 mmHg) and day 8 (-4.0 mmHg) of treatment with valsartan versus placebo. The orthostatic reflex increase in HR was slightly enhanced compared with placebo by an average of 2.8 beats min-1 on day 1 and by 2.9 beats.min-1 on day 8. Valsartan was well tolerated and had no influence on ECG, clinical laboratory parameters, and water, electrolyte and uric acid excretion.\nCONCLUSIONS: Pharmacokinetics of valsartan are unchanged after multiple once-daily dosing, with little (expected) accumulation in plasma. Effects of 200 mg valsartan on blood pressure in healthy subjects on a normal sodium intake are small and become more prominent after repeated dosing. Indirect evidence of AT1 blockade by valsartan is demonstrated by an increase of plasma Ang II and by a blunted DBP response to passive tilting. The decrease in blood pressure at steady state enhances the increase in plasma Ang II. Valsartan is well tolerated and is devoid of effects on water, electrolyte and uric acid excretion at 200 mg per day in healthy normotensive volunteers.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002280050317", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "52"
      }
    ], 
    "name": "Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects", 
    "pagination": "441-449", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fefb1886f58953ae51a92281596a241a6cc2d78c505370e2662bfdab3e0b4591"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9342579"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050317"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053532490"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050317", 
      "https://app.dimensions.ai/details/publication/pub.1053532490"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000483.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s002280050317"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050317'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050317'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050317'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050317'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      21 PREDICATES      59 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050317 schema:about N082351815d2f4b949755c6a3613d1c59
2 N15fca08d2a7e4bfea52b1cc3428f9fb2
3 N23ce27042b0e496bad7b3f4759936d87
4 N35a51f9e7c2c449abbcaeca50c0c7bb6
5 N622d5b4ff6c844d7955ed97c5f66e4a3
6 N65846d1ad1e446cfa610e8c70510f1ff
7 N7218d98b289347d2bb5e8aedd525413b
8 N7241fe6089a342f1a3bef95711fd3db5
9 N888444c0fbc04c7b88e99d3661bef458
10 Na9834eb1e5c2430cbc0af0bf78eb298d
11 Nb7dd837b2c1843539021b566cad001df
12 Nba896820b9c5486cbcc72963495d6013
13 Nbd4f5a8249d843cf9dd8982d452b4460
14 Nd0c6d0eb46474586afd0bda95d1b3d74
15 Ne3dbbe9ab4624f98911aee118a880fc5
16 Ne5cb7e11786740a7a519af093c19854a
17 anzsrc-for:11
18 anzsrc-for:1115
19 schema:author N55bc18313f3046758be4d7ba1b7fa6ba
20 schema:citation sg:pub.10.1007/bf00266358
21 sg:pub.10.1016/0009-9236(95)90020-9
22 sg:pub.10.1016/s0009-9236(96)90061-2
23 sg:pub.10.1016/s0009-9236(97)90180-6
24 sg:pub.10.1038/clpt.1992.56
25 https://doi.org/10.1002/jps.2600810324
26 https://doi.org/10.1016/0006-291x(89)92133-5
27 https://doi.org/10.1042/cs0900205
28 https://doi.org/10.1093/ageing/15.1.17
29 https://doi.org/10.1093/ajh/7.12.1035
30 https://doi.org/10.1097/00004872-199609000-00016
31 https://doi.org/10.1111/j.1365-2125.1993.tb05696.x
32 https://doi.org/10.1161/01.cir.53.3.400
33 https://doi.org/10.1161/01.hyp.22.3.339
34 schema:datePublished 1997-09
35 schema:datePublishedReg 1997-09-01
36 schema:description OBJECTIVE: Pharmacokinetics, pharmacodynamic effects and tolerability of 200 mg valsartan, once-daily for 8 days, were investigated in 16 healthy, normotensive volunteers on a normal sodium diet. METHODS: This was a double-blind, placebo-controlled, randomized crossover study. Drug concentrations in plasma and urine, angiotensin II (Ang II) concentrations in plasma, systolic (SBP) and diastolic (DBP) blood pressure, heart rate (HR) in the supine position and 3 min after passive head-up tilting, as well as safety parameters (ECG, clinical chemistry and hematology, renal water and electrolyte excretion) were measured over 24 h after the first dose (day 1) and at steady state on day 8. RESULTS: Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8). Less than 10% of the dose was excreted unchanged in urine. The increase in plasma Ang II (Cmax, 6 h) was significantly enhanced at steady state. Supine SBP and DBP significantly decreased on day 8 only, by an average of -3.6 and -2.4 mmHg, respectively, versus placebo, without a concomitant increase in HR. Upon passive tilting, the increase in DBP, normally reinforced by sympathetic renin release, was slightly but significantly blunted on day 1 (-2.0 mmHg) and day 8 (-4.0 mmHg) of treatment with valsartan versus placebo. The orthostatic reflex increase in HR was slightly enhanced compared with placebo by an average of 2.8 beats min-1 on day 1 and by 2.9 beats.min-1 on day 8. Valsartan was well tolerated and had no influence on ECG, clinical laboratory parameters, and water, electrolyte and uric acid excretion. CONCLUSIONS: Pharmacokinetics of valsartan are unchanged after multiple once-daily dosing, with little (expected) accumulation in plasma. Effects of 200 mg valsartan on blood pressure in healthy subjects on a normal sodium intake are small and become more prominent after repeated dosing. Indirect evidence of AT1 blockade by valsartan is demonstrated by an increase of plasma Ang II and by a blunted DBP response to passive tilting. The decrease in blood pressure at steady state enhances the increase in plasma Ang II. Valsartan is well tolerated and is devoid of effects on water, electrolyte and uric acid excretion at 200 mg per day in healthy normotensive volunteers.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N978a2f5358964e4db5162ac0f338e28b
41 Nc192627556914d72bbd1d7dc2d144c55
42 sg:journal.1054337
43 schema:name Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
44 schema:pagination 441-449
45 schema:productId N34f1bb528662497d997cc54531b76bdb
46 N4318630905914d5e989c5a09abe273bb
47 Ne322b71ddf2b491191bdd20be4833e26
48 Nee2d2cac22a941f793ed264f3aa3e6c5
49 Nf216f31fbe824c99bead6149a48884a3
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053532490
51 https://doi.org/10.1007/s002280050317
52 schema:sdDatePublished 2019-04-10T19:02
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N76754179adb64b3fac2e1ac257192a3c
55 schema:url http://link.springer.com/10.1007/s002280050317
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N082351815d2f4b949755c6a3613d1c59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Valine
61 rdf:type schema:DefinedTerm
62 N15fca08d2a7e4bfea52b1cc3428f9fb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Blood Pressure
64 rdf:type schema:DefinedTerm
65 N23ce27042b0e496bad7b3f4759936d87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Half-Life
67 rdf:type schema:DefinedTerm
68 N34f1bb528662497d997cc54531b76bdb schema:name pubmed_id
69 schema:value 9342579
70 rdf:type schema:PropertyValue
71 N35a51f9e7c2c449abbcaeca50c0c7bb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Angiotensin II
73 rdf:type schema:DefinedTerm
74 N4318630905914d5e989c5a09abe273bb schema:name nlm_unique_id
75 schema:value 1256165
76 rdf:type schema:PropertyValue
77 N4ee5abec1ae34bc18ce0b0642d2d545e rdf:first sg:person.0607272272.95
78 rdf:rest Nea3ab5d21f4e4098b86dc4f7dc8f7e5a
79 N55bc18313f3046758be4d7ba1b7fa6ba rdf:first sg:person.0601746477.62
80 rdf:rest N6eb70a2368d1488289f7158d2d054cd6
81 N622d5b4ff6c844d7955ed97c5f66e4a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adult
83 rdf:type schema:DefinedTerm
84 N65846d1ad1e446cfa610e8c70510f1ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Cross-Over Studies
86 rdf:type schema:DefinedTerm
87 N6eb70a2368d1488289f7158d2d054cd6 rdf:first sg:person.0614511442.68
88 rdf:rest N4ee5abec1ae34bc18ce0b0642d2d545e
89 N7218d98b289347d2bb5e8aedd525413b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Area Under Curve
91 rdf:type schema:DefinedTerm
92 N7241fe6089a342f1a3bef95711fd3db5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Tetrazoles
94 rdf:type schema:DefinedTerm
95 N76754179adb64b3fac2e1ac257192a3c schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 N888444c0fbc04c7b88e99d3661bef458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Middle Aged
99 rdf:type schema:DefinedTerm
100 N978a2f5358964e4db5162ac0f338e28b schema:issueNumber 6
101 rdf:type schema:PublicationIssue
102 Na9834eb1e5c2430cbc0af0bf78eb298d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Metabolic Clearance Rate
104 rdf:type schema:DefinedTerm
105 Nb7dd837b2c1843539021b566cad001df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antihypertensive Agents
107 rdf:type schema:DefinedTerm
108 Nb94b9bd160f84a71a5a421fb1ef8c849 rdf:first sg:person.01363715465.11
109 rdf:rest rdf:nil
110 Nba896820b9c5486cbcc72963495d6013 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Valsartan
112 rdf:type schema:DefinedTerm
113 Nbd4f5a8249d843cf9dd8982d452b4460 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Double-Blind Method
115 rdf:type schema:DefinedTerm
116 Nc192627556914d72bbd1d7dc2d144c55 schema:volumeNumber 52
117 rdf:type schema:PublicationVolume
118 Nd0c6d0eb46474586afd0bda95d1b3d74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Humans
120 rdf:type schema:DefinedTerm
121 Ne322b71ddf2b491191bdd20be4833e26 schema:name doi
122 schema:value 10.1007/s002280050317
123 rdf:type schema:PropertyValue
124 Ne3dbbe9ab4624f98911aee118a880fc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Heart Rate
126 rdf:type schema:DefinedTerm
127 Ne5cb7e11786740a7a519af093c19854a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Male
129 rdf:type schema:DefinedTerm
130 Nea3ab5d21f4e4098b86dc4f7dc8f7e5a rdf:first sg:person.01344643055.19
131 rdf:rest Nb94b9bd160f84a71a5a421fb1ef8c849
132 Nee2d2cac22a941f793ed264f3aa3e6c5 schema:name dimensions_id
133 schema:value pub.1053532490
134 rdf:type schema:PropertyValue
135 Nf216f31fbe824c99bead6149a48884a3 schema:name readcube_id
136 schema:value fefb1886f58953ae51a92281596a241a6cc2d78c505370e2662bfdab3e0b4591
137 rdf:type schema:PropertyValue
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
142 schema:name Pharmacology and Pharmaceutical Sciences
143 rdf:type schema:DefinedTerm
144 sg:journal.1054337 schema:issn 0031-6970
145 1432-1041
146 schema:name European Journal of Clinical Pharmacology
147 rdf:type schema:Periodical
148 sg:person.01344643055.19 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
149 schema:familyName Gasparini
150 schema:givenName M.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344643055.19
152 rdf:type schema:Person
153 sg:person.01363715465.11 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
154 schema:familyName Howald
155 schema:givenName H.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363715465.11
157 rdf:type schema:Person
158 sg:person.0601746477.62 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
159 schema:familyName Müller
160 schema:givenName P.
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601746477.62
162 rdf:type schema:Person
163 sg:person.0607272272.95 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
164 schema:familyName de Gasparo
165 schema:givenName M.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607272272.95
167 rdf:type schema:Person
168 sg:person.0614511442.68 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
169 schema:familyName Flesch
170 schema:givenName G.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614511442.68
172 rdf:type schema:Person
173 sg:pub.10.1007/bf00266358 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025911538
174 https://doi.org/10.1007/bf00266358
175 rdf:type schema:CreativeWork
176 sg:pub.10.1016/0009-9236(95)90020-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032911978
177 https://doi.org/10.1016/0009-9236(95)90020-9
178 rdf:type schema:CreativeWork
179 sg:pub.10.1016/s0009-9236(96)90061-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042542216
180 https://doi.org/10.1016/s0009-9236(96)90061-2
181 rdf:type schema:CreativeWork
182 sg:pub.10.1016/s0009-9236(97)90180-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008026001
183 https://doi.org/10.1016/s0009-9236(97)90180-6
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/clpt.1992.56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022704315
186 https://doi.org/10.1038/clpt.1992.56
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1002/jps.2600810324 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025971911
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1016/0006-291x(89)92133-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049274476
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1042/cs0900205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056728675
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/ageing/15.1.17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059367722
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1093/ajh/7.12.1035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082472164
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1097/00004872-199609000-00016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013550162
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1111/j.1365-2125.1993.tb05696.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052278669
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1161/01.cir.53.3.400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034907386
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1161/01.hyp.22.3.339 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024651994
205 rdf:type schema:CreativeWork
206 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
207 schema:name Clinical Pharmacology, K-147.3.32, Novartis Pharma AG, CH-4002 Basel, Switzerland Fax +41 (61) 696 55 42, CH
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...